CorPath’s robotic precision and protection from occupational hazards highlighted for attending physicians at CVIT 2015
WALTHAM, MA, July 29, 2015 – Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS], a leading developer of precision vascular robotics, announces that Augusto D. Pichard, M.D., interventional cardiologist at Washington Hospital Center and Professor of Medicine at the George Washington University Medical Center, will discuss how robotic-assisted percutaneous coronary interventions (PCI) are applied in a modern cath lab during his presentation entitled “Robotic Coronary Angioplasty” at the 24thAnnual Meeting of the Japanese Association of Cardiovascular Intervention and Therapeutics: CVIT 2015 in Fukuoka City, Japan, on July 30.
Japan is a large market for interventional cardiology, with 250,000 PCIs performed annually across 1,000 hospitals, and has historically shown interest in robotics and radiation protection. Corindus has been invited by Takafumi Ueno, M.D., Ph.D., President of CVIT 2015, to participate and present the CorPath System in the exhibit hall for hands-on demonstrations to attendees.
"While many devices have been introduced in Japan since the first coronary intervention was performed here more than 35 years ago, we had a limited number of innovations that offered both protection for physicians and potential to improve clinical outcomes," said Dr. Ueno, Professor of Medicine, Cardiovascular Center, Kurume University Hospital. "The interventional cardiology community is open to new ideas and innovative technologies and we welcome the CorPath System to help us explore the advantages a robotic system can add to our practice."
Corindus’ CorPath System is the first FDA-cleared medical device to bring robotically assisted precision to coronary angioplasty procedures in the U.S. The CorPath System is used in cath labs throughout the U.S. for complex PCIs. In addition to allowing cardiologists to advance stents and guidewires with millimeter-by-millimeter precision using digital controls, the system enables physicians to perform procedures while seated in a lead-lined interventional cockpit protected from radiation exposure.
"CorPath is already providing robotic precision during PCI procedures while protecting physicians from the serious occupational hazards in interventional cardiology here in the United States," said David Handler, President and CEO of Corindus. "Japan is an important market for interventional cardiology and it is an honor to be invited to participate in this year’s CVIT conference."
Physicians interested in viewing the CorPath System demonstration during CVIT 2015 need to register in advance. For additional information, visit http://www2.convention.co.jp/cvit2015/en/index.html. For more information about the CorPath System, visit www.corindus.com.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."
For additional information, visit www.corindus.com, and follow @CorindusInc.
Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event
Examples of such statements include statements: